GsMtx-4
Also known as: Grammostola mechanotoxin-4, Grammostola spatulata mechanotoxin 4, GsMTx-4, GsMTx4, Piezo channel inhibitor peptide
Source GsMtx-4 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
GsMTx-4 (Grammostola spatulata mechanotoxin‑4) is a 35‑mer inhibitory cystine‑knot peptide isolated from tarantula venom. It blocks cation‑conducting mechanosensitive (stretch‑activated) ion channels in a variety of eukaryotic cells. In research settings it is used to probe mechanotransduction pathways, to modulate stem‑cell fate, and to test anti‑arrhythmic strategies that target mechanically‑gated channels.
Mechanism of Action
GsMTx-4 inhibits mechanosensitive cation channels, including the Piezo1 stretch‑activated channel, by altering the tension‑sensing properties of the lipid bilayer surrounding the channel. The peptide does not necessarily bind directly to the channel protein; instead it reduces the membrane’s ability to transmit mechanical force, thereby preventing channel opening and the resulting calcium influx that drives downstream signaling.
What the Research Shows
The peptide was first described as the sole pharmacological tool for eukaryotic mechanosensitive channels, blocking cationic SACs in non‑specialized tissues. Experimental studies show that GsMTx-4 suppresses stretch‑induced atrial fibrillation in animal models, suggesting anti‑arrhythmic potential. In human neural stem cells, inhibition of Piezo1 by GsMTx-4 or siRNA reduced calcium‑mediated neurogenesis and favored astrogenesis, linking mechanosensitive signaling to lineage choice. Reviews highlight its unique status among MSC modulators (gadolinium, streptomycin) and propose it as a template for novel therapeutics, although its precise binding interactions and in‑vivo efficacy remain under investigation.
Reported Benefits
GsMTx-4 provides a selective means to block mechanosensitive cation channels, enabling dissection of mechanical signaling in cellular physiology. It has demonstrated ability to prevent stretch‑facilitated atrial fibrillation in experimental settings and to influence stem‑cell differentiation by modulating Piezo1 activity. These properties make it valuable for mechanobiology research and as a prototype for future anti‑arrhythmic drug development.
Limitations of the Evidence
Evidence for GsMTx-4 is confined to in‑vitro experiments and animal models; no clinical trials have been reported. The exact molecular target and binding mode are not fully resolved, and off‑target effects on normal mechanotransduction pathways are possible. Its therapeutic potential remains speculative, and translation to human use will require extensive safety and efficacy testing.
Safety Considerations
The abstracts do not detail adverse effects, but as a venom‑derived peptide that blocks essential mechanosensitive channels, unintended inhibition of physiological mechanotransduction could occur. Toxicity, immunogenicity, and dose‑related safety data are lacking, so cautious handling and thorough preclinical safety evaluation are warranted before any translational application.
How It Is Administered
Research applications of GsMTx-4 have employed intrathecal, intravenous, subcutaneous, and topical routes, typically using peptide solutions formulated for experimental delivery. Formulation specifics (e.g., buffers, carriers) are not described in the cited literature and are determined by individual study protocols.
Routes of Administration
Goals & Uses
- Muscular dystrophy (Duchenne) treatmentNeuromuscular DiseaseLow
- Research tool – mechanotransduction studiesResearchHigh
- Cardioprotection during ischemiaCardiovascular / CardioprotectionLow
- Atrial fibrillation suppressionCardiovascularLow
- Neuroprotection after traumatic brain injuryNeurologicalLow
- Neuropathic pain reliefPain / NeurologyModerate
- Pulmonary arterial hypertensionCardiovascular / PulmonaryLow
Contraindications
- Known hypersensitivity to spider venom peptidesAllergy / ImmunologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Human clinical useRegulatoryHigh
Adverse Effects
- Cardiovascular depressionCardiovascularUnknown
- HypotensionCardiovascularUncommonLow blood pressure
- Immune/allergic reactionImmunologicalUnknown
- Off-target channel inhibitionPharmacologicalUncommon
Drug Interactions
- Other mechanosensitive channel modulatorsLow
Population Constraints
- Pregnant or lactating individualsReproductiveRelative
- Pediatric populationsAgeRelative
- Patients with cardiac arrhythmiasCardiovascularRelative
- Pediatric useAgeRelative
Regulatory Status
- European UnionResearchNot authorized for clinical use.
- United StatesResearchInvestigational use only in preclinical studies.
- United KingdomUnapprovedNo MHRA approval; research reagent only.
Not approved for human use; available only for preclinical research.
Evidence & Sources
- Journal ArticleModerateBowman CL, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleModeratePathak MM, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateWhite E2006-01-01T00:00:00.000000Z
- Journal ArticleModerateRebello Horta CC, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateFranz MR, Bode F2003-01-01T00:00:00.000000Z
- Journal ArticleModerateSokabe M, Naruse K, Qiong-Yao T2004-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of protein is GsMTx-4?
GsMTx-4 is an inhibitory cystine‑knot (ICK) peptide consisting of 35 amino acids. It is derived from the venom of the tarantula Grammostola spatulata and belongs to the family of peptide toxins that block mechanosensitive ion channels.
Can GsMTx-4 be used to treat heart rhythm disorders in patients?
Current evidence is limited to experimental models where GsMTx-4 suppressed stretch‑induced atrial fibrillation. No human clinical trials have been reported, and the peptide is not approved for therapeutic use; it remains a research tool.
How does GsMTx-4 affect stem‑cell differentiation?
In human neural stem cells, GsMTx-4 inhibits the Piezo1 channel, reducing calcium influx that normally promotes neurogenesis. This inhibition shifts differentiation toward astrocyte formation, demonstrating that mechanosensitive signaling influences lineage choice.
Is GsMTx-4 safe to use in laboratory animals?
The cited studies do not report specific toxicities, but because GsMTx-4 blocks essential mechanosensitive channels, unintended physiological effects are possible. Safety assessments are performed on a case‑by‑case basis in each experimental protocol.
What routes are used to deliver GsMTx-4 in research?
Researchers have administered GsMTx-4 intrathecally, intravenously, subcutaneously, and topically, depending on the experimental design. The peptide is typically delivered in solution, with formulation details varying across studies.
What is GsMtx-4?
GsMTx-4 (Grammostola spatulata mechanotoxin‑4) is a 35‑mer inhibitory cystine‑knot peptide isolated from tarantula venom. It blocks cation‑conducting mechanosensitive (stretch‑activated) ion channels in a variety of eukaryotic cells. In research settings it is used to probe mechanotransduction pathways, to modulate stem‑cell fate, and to test anti‑arrhythmic strategies that target mechanically‑gated channels.
What is GsMtx-4 used for?
GsMtx-4 is educationally associated with: Muscular dystrophy (Duchenne) treatment, Research tool – mechanotransduction studies, Cardioprotection during ischemia, Atrial fibrillation suppression, Neuroprotection after traumatic brain injury, Neuropathic pain relief, Pulmonary arterial hypertension. Educational only — not medical advice.
How is GsMtx-4 administered?
Recorded routes of administration: Intracerebroventricular, Intraperitoneal, Intrathecal, Intravenous, Subcutaneous, Topical (research).
What are the potential side effects of GsMtx-4?
Reported adverse effects include: Cardiovascular depression, Hypotension, Immune/allergic reaction, Off-target channel inhibition. This list is not exhaustive — consult a qualified clinician.
Who should avoid GsMtx-4?
Recorded contraindications: Known hypersensitivity to spider venom peptides, Pregnancy, Human clinical use. Consult a qualified clinician before use.